PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury.

Phase 4

Withdrawn

Conditions: Brain Injuries

First Posted Date: 2007-02-07

Last Posted Date: 2015-04-22

Lead Sponsor: Pfizer

Registration Number: NCT00432263

Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.

Phase 2

Terminated

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: UK-432,097
Drug: Placebo

First Posted Date: 2007-02-01

Last Posted Date: 2013-07-08

Lead Sponsor: Pfizer

Target Recruit Count: 87

Registration Number: NCT00430300

Locations: 🇬🇧
Pfizer Investigational Site, Southampton, United Kingdom

A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

Phase 3

Terminated

Conditions: Carcinoma, Islet Cell
Carcinoma, Pancreas

Interventions: Drug: Placebo
Drug: sunitinib malate

First Posted Date: 2007-01-30

Last Posted Date: 2010-10-11

Lead Sponsor: Pfizer

Target Recruit Count: 171

Registration Number: NCT00428597

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

Maraviroc in Rheumatoid Arthritis

Phase 2

Terminated

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Maraviroc Placebo
Drug: Maraviroc

First Posted Date: 2007-01-29

Last Posted Date: 2014-11-05

Lead Sponsor: Pfizer

Target Recruit Count: 128

Registration Number: NCT00427934

Locations: 🇺🇦
Pfizer Investigational Site, Simferopol, Ukraine

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Not Applicable

Completed

Conditions: Pancreatic Islet Cell Carcinoma
Advanced/Metastatic Non-Small Cell Lung Cancer
Metastatic Breast Cancer
Advanced Breast Cancer
Thyroid Cancer
Hepatocellular Carcinoma
Metastatic Castration Resistant Prostate Cancer
Metastatic Renal Cell Cancer
Non-Small Cell Lung Cancer
Advanced Gastric Cancer

Interventions: Drug: sunitinib

First Posted Date: 2007-01-29

Last Posted Date: 2019-06-27

Lead Sponsor: Pfizer

Target Recruit Count: 223

Registration Number: NCT00428220

Locations: 🇨🇳
Chi-Mei Medical Center, YungKang City, Tainan, Taiwan
🇨🇴
Fundacion Centro de Investigacion Clinica CIC, Medellin, Anquioquia, Colombia
🇦🇺
Austin Health, Heidelberg, Victoria, Australia

and more 109 locations

Colombia Epidemiologic Surveillance Study

Terminated

Conditions: Pneumonia
Meningitis
Bacteremia
Sepsis

Interventions: Other: Surveillance

First Posted Date: 2007-01-29

Last Posted Date: 2011-10-27

Lead Sponsor: Pfizer

Target Recruit Count: 32867

Registration Number: NCT00428051

Locations: 🇨🇷
Pfizer Investigational Site, La Uruca, San Jose, Costa Rica

A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks

Phase 2

Terminated

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2007-01-29

Last Posted Date: 2008-09-29

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT00427401

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)
Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)

First Posted Date: 2007-01-29

Last Posted Date: 2021-11-15

Lead Sponsor: Pfizer

Target Recruit Count: 2141

Registration Number: NCT00427895

Locations: 🇺🇸
Kentucky Pediatric /Adult Research, Bardstown, Kentucky, United States
🇺🇸
J. Lewis Research/First Med, West Jordan, Utah, United States
🇺🇸
Heartland Research Associates, LLC, Wichita, Kansas, United States

and more 18 locations

A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: fesoterodine fumarate

First Posted Date: 2007-01-22

Last Posted Date: 2018-12-05

Lead Sponsor: Pfizer

Target Recruit Count: 516

Registration Number: NCT00425100

Locations: 🇺🇦
Pfizer Investigational Site, Zaporizhzhia, Ukraine

Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Biological: IMA-638
Other: placebo

First Posted Date: 2007-01-22

Last Posted Date: 2015-01-14

Lead Sponsor: Pfizer

Target Recruit Count: 159

Registration Number: NCT00425061

Locations: 🇺🇸
Allergy and Clinical Immunology, Pittsburgh, Pennsylvania, United States
🇺🇸
Allergy and Asthma Care Center of Southern California, Long Beach, California, United States
🇺🇸
Alabama Allergy & Asthma Clinic, Montgomery, Alabama, United States

and more 77 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy